The Notch signaling pathway represents one of the most evolutionarily conserved intercellular communication mechanisms in multicellular organisms. Originally identified in Drosophila melanogaster where Notch mutations caused notches in fly wings, this pathway now recognized as a critical regulator of cell fate, differentiation, proliferation, and apoptosis throughout the nervous system 1. In the context of neurodegeneration, Notch signaling plays complex and often contradictory roles, contributing to both neuroprotective processes and pathological mechanisms in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions 2. [1]
Notch receptors are transmembrane proteins that mediate direct cell-cell communication through ligand binding. The mammalian genome encodes four Notch receptors (Notch1-4) and five ligands (Delta-like 1, 3, 4 and Jagged 1, 2). Upon ligand binding, proteolytic cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and regulates gene expression through interaction with CSL (CBF1/Su(H)/Lag-1) transcription factors and co-activators of the Mastermind family 3. [2]
Notch receptors are type I transmembrane proteins composed of multiple domains: [3]
Extracellular domain (NECD): [4]
Transmembrane domain: [5]
Intracellular domain (NICD): [6]
Notch activation requires two sequential proteolytic cleavages: [7]
S1 cleavage (constitutive): [8]
S2 cleavage (regulated): [9]
S3 cleavage (regulated): [10]
Once in the nucleus, NICD regulates transcription: [11]
CSL-dependent transcription: [12]
Key target genes: [13]
Notch can signal independently of CSL: [14]
Non-nuclear signaling: [15]
Ligand-independent activation: [16]
Alzheimer's disease involves complex interactions between Notch signaling and amyloid pathology: [17]
Notch processing alterations: [18]
Transcriptional dysregulation: [19]
Therapeutic implications: [20]
Notch signaling interacts with tau pathology: [21]
Tau phosphorylation effects: [22]
Tau and Notch in synaptic function: [23]
Notch regulates neural stem cell function: [24]
Adult neurogenesis: [25]
Therapeutic potential: [26]
Notch plays essential roles in dopaminergic neuron development: [27]
Development regulation: [28]
Adult function: [29]
α-Synuclein pathology affects Notch signaling: [30]
Pathological interactions: [31]
Neuroinflammation: [32]
Targeting Notch in PD: [33]
Notch inhibitors: [34]
Notch activators: [35]
Notch signaling is critical for motor neuron biology: [36]
Development: [37]
ALS implications: [38]
Notch mediates glial contributions to ALS: [39]
Astrocyte dysfunction: [40]
Microglial activation:
Notch signaling alterations in HD:
Transcriptional dysregulation:
Therapeutic targeting:
Notch in demyelinating diseases:
Oligodendrocyte function:
Immune modulation:
Notch is essential for synaptic plasticity:
Long-term potentiation (LTP):
Long-term depression (LTD):
Notch regulates neuronal morphology:
Spine development:
Axon guidance:
Modulating Notch processing:
Notch-sparing inhibitors:
γ-secretase modulators (GSMs):
Specific Notch pathway interventions:
Notch antibodies:
Notch transcription complex inhibitors:
Genetic modulation of Notch:
Notch gene therapy:
CRISPR applications:
Notch pathway markers:
Peripheral measurements:
CSF markers:
Tracking Notch modulation:
Target engagement markers:
Studying Notch in neurodegeneration:
Cell culture models:
Animal models:
In vitro systems:
The Notch signaling pathway plays complex roles in neurodegeneration, with both protective and detrimental effects depending on context, cell type, and disease stage. Understanding the nuanced functions of Notch in Alzheimer's disease, Parkinson's disease, ALS, and other conditions provides opportunities for therapeutic intervention. The challenge lies in developing strategies that modulate Notch signaling sufficiently to provide benefit while avoiding the adverse effects associated with broad pathway inhibition. As our understanding of Notch biology in the nervous system advances, more targeted approaches may emerge that harness the pathway's regenerative potential while mitigating pathological effects.
" Iso T, Kedes L, Hamamori Y. HES and HERP families. Dev Cell. 2003;4(2):169-181". 2003. ↩︎
" Andersson ER, Lendahl U. Non-canonical Notch signaling. Nat Rev Cancer. 2014;14(2):121-134". 2014. ↩︎
Gazdar A, et al. " Notch mutations. Oncogene. 2000;19(43):4902-4906". 2000. ↩︎
Berezovska O, et al. " Notch and amyloid. J Neurochem. 2001;79(1):1-8". 2001. ↩︎
Wesenbeek GP, et al. " Notch transcription in AD. Neurobiol Aging. 2004;25(3):329-338". 2004. ↩︎
" Selkoe D, Kopan R. Notch and amyloid. Annu Rev Neurosci. 2003;26:565-597". 2003. ↩︎
Lathia JD, et al. " Notch, tau and neurodegeneration. J Neurosci. 2008;28(35):8644-8654". 2008. ↩︎
Wang R, et al. " Notch and synaptic plasticity. J Neurosci. 2006;26(40):10020-10028". 2006. ↩︎
Kageyama R, et al. " Notch and neurogenesis. Dev Neurosci. 2005;27(1):1-8". 2005. ↩︎
Aguirre A, et al. " Notch and neural stem cells. Nat Rev Neurosci. 2010;11(5):311-323". 2010. ↩︎
Prakash N, et al. " Notch and dopamine neurons. Development. 2006;133(1):89-100". 2006. ↩︎
Stott SR, et al. " Notch in adult dopamine neurons. J Comp Neurol. 2011;519(15):3004-3020". 2011. ↩︎
Matsell E, et al. " Alpha-synuclein and Notch. Neurobiol Dis. 2013;59:233-244". 2013. ↩︎
Grandbarbe L, et al. " Notch and neuroinflammation. Eur J Neurosci. 2007;26(3):477-486". 2007. ↩︎
Weidenfeld J, et al. " Notch inhibition in PD. Mov Disord. 2012;27(8):925-934". 2012. ↩︎
Ramos C, et al. " Notch activation in PD. J Neurosci. 2010;30(42):14025-14035". 2010. ↩︎
Stott SR, et al. " Notch and motor neuron development. Dev Biol. 2013;382(2):400-410". 2013. ↩︎
Lino MM, et al. " Notch in ALS. Exp Neurol. 2012;237(1):47-53". 2012. ↩︎
Trias E, et al. " Astrocyte Notch in ALS. Glia. 2013;61(11):1753-1765". 2013. ↩︎
Zhang Y, et al. " Microglial Notch signaling. J Neuroinflammation. 2015;12:151". 2015. ↩︎
Benevento M, et al. Notch in Huntington's disease. Hum Mol Genet. 2016;25(11):2242-2255. 2016. ↩︎
Huang K, et al. " Notch targeting in HD. Neurobiol Dis. 2017;108:137-148". 2017. ↩︎
Zhang Y, et al. " Notch and remyelination. Nat Neurosci. 2009;12(6):815-824". 2009. ↩︎
Minter LM, et al. " Notch and T cells. Nat Rev Immunol. 2015;15(10):599-612". 2015. ↩︎
Costa RM, et al. " Notch and synaptic plasticity. Proc Natl Acad Sci U S A. 2003;100(16):9574-9579". 2003. ↩︎
Wang Y, et al. " Notch and LTD. J Neurosci. 2004;24(42):9256-9265". 2004. ↩︎
Yoshikawa K, et al. " Notch and dendritic spines. Development. 2007;134(16):2969-2979". 2007. ↩︎
Kawaguchi D, et al. " Notch and axon guidance. Development. 2013;140(9):1889-1898". 2013. ↩︎
Basi GS, et al. " Notch-sparing gamma-secretase inhibitors. J Biol Chem. 2010;285(29):22192-22203". 2010. ↩︎
Kounnas MZ, et al. " Gamma-secretase modulators. J Neurosci. 2010;30(16):5419-5428". 2010. ↩︎
Wu Y, et al. " Therapeutic antibodies to Notch. Nat Rev Drug Discov. 2010;9(10):807-821". 2010. ↩︎
Moellering RE, et al. " Direct inhibition of Notch. Nat Chem Biol. 2009;5(3):154-156". 2009. ↩︎
Luo D, et al. " Notch gene therapy. Mol Ther. 2015;23(2):226-236". 2015. ↩︎
Henao-Mejia J, et al. " CRISPR and Notch. Cell. 2016;166(2):261-267". 2016. ↩︎
Benedict CA, et al. " Soluble Notch receptors. J Immunol. 2000;165(9):5127-5132". 2000. ↩︎
Kopan R, et al. " Notch in CSF. Nat Med. 2012;18(8):1158-1159". 2012. ↩︎
Liu J, et al. " Notch pathway biomarkers. J Neurochem. 2016;139(2):216-228". 2016. ↩︎
Noggle SA, et al. " Notch in neuronal differentiation. Nat Biotechnol. 2008;26(3):313-320". 2008. ↩︎
Ishibashi M, et al. " Notch transgenic mice. Nature. 1995;377(6550):703-706". 1995. ↩︎
Muguruma K, et al. " Brain organoids. J Neurosci. 2015;35(44):14842-14850". 2015. ↩︎